Related Experiment Video
Updated: May 20, 2026

Wireless Telemetry Device Implantation in a Fontan Ovine Model for Continuous and Long-Term Hemodynamic Monitoring
Published on: May 2, 2025
Long-Term Care in Fontan Circulation: Surveillance and Management of Fontan-Associated Liver Disease and
Chaowapong Jarasvaraparn1, Gary R Schooler2, Iván A González3
1Division of Pediatric Gastroenterology, Hepatology and Nutrition, Indiana University, 705 Riley Hospital Drive, ROC 4210, Indianapolis, IN, 46202, USA. cjarasva@iu.edu.
Insights
Fontan-associated liver disease (FALD) and protein-losing enteropathy (PLE) are common after the Fontan procedure. Early recognition and multidisciplinary management are crucial for improving outcomes in these patients.
Area of Science:
- Cardiology
- Hepatology
- Pediatric Gastroenterology
Background:
- The Fontan procedure creates a unique physiology leading to chronic venous hypertension.
- This venous hypertension results in multisystem injury, notably affecting the liver and gastrointestinal tract.
Purpose of the Study:
- To review the clinical spectrum and management of Fontan-associated liver disease (FALD).
- To examine protein-losing enteropathy (PLE) in the context of Fontan physiology.
- To understand how chronic venous hypertension contributes to multisystem injury.
Main Methods:
- Literature review of clinical studies and case reports.
- Analysis of current understanding of Fontan circulation pathophysiology.
- Synthesis of management strategies for FALD and PLE.
Main Results:
- Liver fibrosis is a nearly universal complication, with cirrhosis affecting 43% by 30 years post-Fontan.
- Standard biomarkers and imaging may underestimate FALD severity due to hepatic congestion.
- Liver biopsy is the gold standard for staging FALD.
- PLE results from multifactorial gastrointestinal protein loss.
- A multidisciplinary approach is essential, especially for combined heart-liver transplantation in advanced cases.
Conclusions:
- Fontan-associated liver disease (FALD) and protein-losing enteropathy (PLE) are inevitable consequences of Fontan physiology.
- Standard diagnostic tools may be insufficient for accurate FALD staging.
- Future research needs standardized staging and targeted therapies for lymphatic dysfunction and fibrosis progression.
Purpose Of Review:
This manuscript reviews the clinical spectrum and management of Fontan-associated liver disease (FALD) and protein-losing enteropathy (PLE), examining how chronic venous hypertension leads to multisystem injury.
Recent Findings:
Liver fibrosis is now recognized as an early and nearly universal complication after the Fontan procedure, with cirrhosis affecting approximately 43% of patients by 30 years post-operation. Although post-2001 survival exceeds 90%, standard biomarkers and imaging frequently underestimate disease severity, as liver stiffness measurements are confounded by hepatic congestion. Liver biopsy remains the gold standard for staging. FALD is an inevitable consequence of Fontan physiology, characterized by sinusoidal congestion and progressive fibrosis, while PLE results from multifactorial gastrointestinal protein loss. The key clinical implication is the importance of a multidisciplinary approach, particularly when considering transition from isolated heart transplantation to combined heart-liver transplantation in advanced disease. Future research should prioritize standardized staging systems and targeted therapies to reduce lymphatic dysfunction and fibrosis progression.
Related Concept Videos
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Chronic Pancreatitis II: Collaborative Care
Assessment:
Nephrotic Syndrome III : Nursing Management
Chronic Kidney Disease IV: Nursing Management
Mitral Regurgitation IV: Nursing Management
Endocarditis IV: Nursing Management